Based on the available information, there is no explicit statement regarding the safety of administering live vaccines while on Cosentyx (secukinumab) [1][2]. However, according to the NCBI article, there is a general recommendation that live vaccines should be avoided in immunocompromised patients, as they might not develop a sufficient immune response, and there could be a risk of adverse events [3]. Secukinumab, the active ingredient in Cosentyx, is a monoclonal antibody that targets interleukin-17A, which plays a role in inflammatory processes [1][2]. By inhibiting IL-17A, Cosentyx can help treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2].

Given that Cosentyx can affect the immune system, it is crucial to consult healthcare professionals for personalized advice regarding vaccinations [3]. They can evaluate the patient's condition and determine the most appropriate course of action, considering factors such as the specific vaccine and the patient's health status [3].

In summary, while there is no specific information on the safety of live vaccines and Cosentyx, immunocompromised patients should generally avoid live vaccines due to potential risks and reduced efficacy [3]. It is essential to consult healthcare professionals for personalized advice regarding vaccinations while on Cosentyx.

Sources:
[1] <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>
[2] <https://www.cosentyx.com/all/covid19>
[3] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767096/>